Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 9, 2015 - Issue 6
Submit an article Journal homepage
1,428
Views
4
CrossRef citations to date
0
Altmetric
Editorials

Which patients with inflammatory bowel disease should receive combination therapy?

Raymond K CrossDepartment of Medicine, Division of Gastroenterology and Hepatology, University of Maryland, 100 North Greene Street, LL Baltimore, MD 21201, USACorrespondence[email protected]
Pages 715-717 | Published online: 25 Apr 2015

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Carlos Taxonera, Fernando de Andrés-Nogales, Santiago García-López, Amelia Sánchez-Guerrero, Belén Menchén, Carmen Peral, Ana Cábez, Susana Gómez, Alejandra López-Ibáñez de Aldecoa, Miguel Ángel Casado & Luis Menchén. (2022) Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Review of Pharmacoeconomics & Outcomes Research 22:1, pages 73-83.
Read now

Articles from other publishers (3)

Marisa Iborra, Natalia García-Morales, Saoia Rubio, Federico Bertoletti, Marta Calvo, Carlos Taxonera, Marta Maia Boscá-Watts, Mónica Sierra, Noemí Mancenido, Belén Beltrán, Óscar Nantes Castillejo, Esther García-Planella, Isabel Vera, Cristina Alba, David Martí-Aguado, María Pilar Ballester, Noelia Cano-Sanz, Ramón Pajares-Villarroya, Elena Cerrillo, Antonio Cañada & Pilar Nos. (2020) Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. Scientific Reports 10:1.
Crossref
Brian G. Feagan, David T. Rubin, Silvio Danese, Severine Vermeire, Brihad Abhyankar, Serap Sankoh, Alexandra James & Michael Smyth. (2017) Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. Clinical Gastroenterology and Hepatology 15:2, pages 229-239.e5.
Crossref
Marina Aloi & Salvatore Cucchiara. (2015) Predicting the Durability of Biological Therapy in Pediatric Crohn’s Disease: Do the Immunomodulators Matter?. Clinical Gastroenterology and Hepatology 13:10, pages 1757-1759.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.